Top Markets
#1 Black Phoenix Black Phoenix +166.52%
#2 Islamic Coin Islamic Coin +158.25%
#3 Glidr Glidr +84.34%
#4 Test Test +21.69%
#5 Cryptopia Cryptopia +21.17%
#6 Quantum Resistant Ledger Quantum Resistant Ledger +18.52%
#7 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +18.45%
#8 Wrapped Bitcoin (PulseChain) Wrapped Bitcoin (PulseChain) +12.47%
#9 MarsCoin MarsCoin +11.59%
#10 DOVU DOVU +8.82%
Coin of the day
Black Phoenix Black Phoenix
Pengaturan
Bahasa
BAHASA INDONESIA
Mata uang
USD
Tema
InNexus Biotechnology, Inc. InNexus Biotechnology, Inc.

InNexus Biotechnology, Inc.

IXSBF
Peringkat dalam Saham #41697
InNexus Biotechnology, Inc. is a development-stage company dedicated to... InNexus Biotechnology, Inc. is a development-stage company dedicated to advancing and commercializing monoclonal antibodies. Its efforts are underpinned by its proprietary Dynamic Cross Linking (DXL) technology. This DXL platform is designed to boost the therapeutic efficacy of conventional monoclonal antibody treatments by strengthening their binding to target antigens, amplifying their effector functions, and endowing them with novel properties. InNexus's development portfolio features several investigational therapies: DXL625: A monoclonal antibody currently in late-stage pre-clinical development, engineered for superior binding kinetics and enhanced effector functions, intended for treating B-cell non-Hodgkin's lymphoma (NHL). DXLr120: A recombinant DXL anti-CD20 antibody also being developed for B-cell NHL. DXL702: A monoclonal antibody targeting metastatic breast cancer. DXL1218: An agent designed to target the epidermal growth factor receptor (EGFR), an antigen frequently overexpressed in metastatic colorectal cancer and squamous cell carcinomas of the head and neck. The company also maintains strategic partnerships with XERIS Pharmaceuticals, Genhelix, Evogenix, Affimed, and Corixa. InNexus Biotechnology, Inc. is based in Vancouver, Canada.
Harga Saham
$0.0001
Terakhir disinkronkan: 2025-11-07
Kapitalisasi Pasar
$12.63K
Perubahan (1 hari)
0.00%
Perubahan (1 tahun)
0.00%
Negara
CA
Perdagangan InNexus Biotechnology, Inc. (IXSBF)

Kategori

Healthcare
Pendapatan untuk InNexus Biotechnology, Inc. (IXSBF)
Pendapatan pada Aug 2026 TTM: 0
Menurut laporan keuangan terbaru dari InNexus Biotechnology, Inc., pendapatan saat ini (TTM) adalah 0. Pada tahun 2026, perusahaan menghasilkan pendapatan sebesar 0 sama dengan pendapatan pada tahun 2026 yang sebesar 0. Pendapatan adalah jumlah total yang dihasilkan dari penjualan barang atau jasa. Tidak seperti laba, tidak ada pengeluaran yang dikurangkan.
Riwayat pendapatan InNexus Biotechnology, Inc. dari 2026 hingga 2026
Pendapatan pada akhir setiap tahun
Tahun Pendapatan Mengubah
Tidak cukup data untuk tanggal yang disediakan.
Pendapatan untuk perusahaan serupa atau pesaing
Perusahaan Pendapatan Perbedaan Pendapatan Negara
Royalty Pharma plc Royalty Pharma plc
Royalty Pharma plc
RPRX.US
 $2.54B -
US
Swedish Orphan Biovitrum AB Swedish Orphan Biovitrum AB
Swedish Orphan Biovitrum AB
SOBI.ST
 - -
SE
Ipsen S.A. Ipsen S.A.
Ipsen S.A.
IPN.PA
 - -
FR
Recordati Industria Chimica e Farmaceutica S.p.A. Recordati Industria Chimica e Farmaceutica S.p.A.
Recordati Industria Chimica e Farmaceutica S.p.A.
REC.MI
 - -
IT
Corcept Therapeutics Incorporated Corcept Therapeutics Incorporated
Corcept Therapeutics Incorporated
CORT.US
 $830.81M -
US